| Line Item | 2024-11-30 | Y/Y |
|---|---|---|
| Revenue | $54.5M | -29.1% |
| R&D Expense | $221.6M | +17.2% |
| SG&A Expense | $45.9M | +7.1% |
| Operating Income | -$213.0M | -37.4% |
| Pre-tax Income | -$193.3M | -34.3% |
| Income Tax | $270K | — |
| Net Income | -$193.6M | -34.5% |
| EPS (Basic) | -$2.88 | -8.7% |
| EPS (Diluted) | -$2.88 |
| Line Item | 2024-11-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $110.0M | +101.4% |
| Current Assets | $619.4M | +109.6% |
| Total Assets | $669.3M | +88.2% |
| Current Liabilities | $95.9M | +10.2% |
| Total Liabilities | $142.3M | -8.2% |
| Stockholders' Equity | $527.0M | +162.8% |
| Line Item | 2024-11-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$172.6M | -112.1% |
| Capital Expenditures | $9.3M | +10.4% |
| Investing Cash Flow | -$257.7M | -477.3% |
| Financing Cash Flow | $485.7M | — |
| Free Cash Flow | -$181.9M | -102.6% |
| -8.7% |